Cryo-Cell International (NYSEAMERICAN:CCEL) Stock Price Crosses Below 200-Day Moving Average – Here’s Why

Posted by Chris Copeland on Jul 10th, 2026

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL – Get Free Report) shares passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $3.45 and traded as low as $3.43. Cryo-Cell International shares last traded at $3.43, with a volume of 4,183 shares trading hands.

Cryo-Cell International Stock Performance

The firm has a market capitalization of $27.57 million, a P/E ratio of -10.36 and a beta of 0.49. The business has a fifty day moving average of $3.52 and a 200-day moving average of $3.45.

Cryo-Cell International (NYSEAMERICAN:CCEL – Get Free Report) last released its quarterly earnings results on Tuesday, April 14th. The company reported $0.01 earnings per share (EPS) for the quarter. The business had revenue of $7.68 million during the quarter.

Institutional Investors Weigh In On Cryo-Cell International

An institutional investor recently bought a new position in Cryo-Cell International stock. Susquehanna International Group LLP purchased a new stake in shares of Cryo-Cell International Inc. (NYSEAMERICAN:CCEL – Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned 0.14% of Cryo-Cell International as of its most recent filing with the Securities and Exchange Commission. 10.44% of the stock is owned by hedge funds and other institutional investors.

Cryo-Cell International Company Profile

(Get Free Report)

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.